Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase IIb clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.